CAS 1476807-74-5

Formula: C18H17BrN2O2S

InChI: InChI=1S/C18H17BrN2O2S/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(24(20,22)23)8-9-17(16)21-18/h1-2,4-10,14-15,18,21H,3H2,(H2,20,22,23)/t14-,15+,18+/m0/s1

InChI key: YNCXHXYZTLIZTO-HDMKZQKVSA-N

SMILES: C1C=C[C@H]2[C@@H]1[C@H](NC3=C2C=C(C=C3)S(=O)(=O)N)C4=CC=C(C=C4)Br

GAT107

CAS: 1476807-74-5

GAT107

Formula: C₁₈H₁₇BrN₂O₂S

Purity: 99%

Molecular weight: 405.31

Ref: 54-BUP07901

GAT107

CAS: 1476807-74-5

Formula: C₁₈H₁₇BrN₂O₂S

Molecular weight: 405.3088

Ref: IN-DA01EQFD

GAT107

CAS: 1476807-74-5

GAT107, a strong α7 nicotinic receptor modulator, aids inflammation and neuropathic pain in mice.

Formula: C₁₈H₁₇BrN₂O₂S

Purity: 99.33%

Color and Shape: White Solid

Molecular weight: 405.31

Ref: TM-T27404

GAT107

CAS: 1476807-74-5

GAT107 is a cholinergic agonist that binds to the nicotinic acetylcholine receptor and activates it. It has been shown to have anti-inflammatory effects, including an induction of IL-10 production, which may be due to its binding to the α7 nicotinic acetylcholine receptor. GAT107 also has antinociceptive properties in animal models and can be used for the treatment of inflammatory diseases such as rheumatoid arthritis. GAT107 is structurally related to 4-bromotryptamine (4bp-tqs) and binds selectively to the acetylcholine receptor at the activated state. It is also a cation channel activator and inhibits voltage-gated calcium channels by interacting with their pore region.

Formula: C₁₈H₁₇BrN₂O₂S

Purity: Min. 95%

Molecular weight: 405.3 g/mol

Ref: 3D-BJC80774